- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01222286
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma (KIRMONO)
Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)
Study Overview
Detailed Description
This is a randomized Phase II, open label, multi-centre study, with two independent arms.
Patients receive 6 injections of IPH2101, at the dose of 0.2 mg/kg or 2 mg/kg (according to their randomization) administered over one hour infusion at four weeks intervals.
A patient whose disease achieves at least a minimal response to study treatment at any time during the initial period of 6 cycles can be treated with an additional period of treatment of 6 cycles.
Patients are followed 6 months after treatment completion or until a KIR occupancy level < 30% (i.e if the time required for KIR desaturation was > 6 months), whichever is longer.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
SMM of any risk level according to a definition derived of the International Myeloma Working Group definition ( Br J Haematol 2003; 121: 749) : Serum M protein ≥ 3 g/dl , AND/OR Bone Marrow plasma cells ≥ 10 % with no evidence of end-organ damage (CRAB)
- (C)Absence of hypercalcemia : Ca < 10.5 mg/dl
- (R)Absence of renal failure : creatinine < 2mg/dl (177 μmol/l) or calculated creatinine clearance(according to MDRD) > 50 ml/min
- (A)Absence of anemia : Hb > 11 g/dl
- (B)Absence of lytic bone lesion on standard skeletal survey (MRI could be used if clinically indicated)
- Measurable disease defined as a disease with a serum M protein ≥ 1 g/dl
- No evidence of fatigue, recurrent infections or any clinical suspicion of MM
- Diagnosis of SMM confirmed on two consecutive assessments (ie fluctuation under 25% of serum protein level) performed with at least a 4 week interval.
- Age > 18 years or < 75 years
- ECOG performance status of 0 or 1
- Male or female patient who accepts and is able to use recognised effective contraception (oral contraceptives, IUCD, barrier method of contraception in conjunction with spermicidal jelly) throughout the study when relevant
- Informed consent signed by the patient
Exclusion Criteria:
- Previous treatment having a proven or potential impact on myelomatous cells proliferation or survival (including IMiDs or proteasome inhibitors, conventional chemotherapies within the last 5 years, steroids within the last month prior to enrolment). Previous bisphosphonates started less than 3 months prior to enrolment.
- Use of any investigational agent within the last 3 months
Clinical laboratory values at screening
- Platelet < 75 x 10^9 /l
- ANC < 1.5 x 10^9 /l
- Bilirubin levels >1.5 ULN ; ALT and AST > 3 ULN (grade 1 NCI)
- Primary or associated amyloidosis
Abnormal cardiac status with any of the following
- NYHA stage III or IV congestive heart failure
- myocardial infarction within the previous 6 months
- symptomatic cardiac arrhythmia requiring treatment or persisting despite appropriate treatment
- Current active infectious disease or positive serology for HIV, HCV or positive Hbs Antigen
- History of or current auto-immune disease
- History of other active malignancy within the past five years (apart from basal cell carcinoma of the skin, or in situ cervix carcinoma).
- Serious concurrent uncontrolled medical disorder
- History of allograft or solid organ transplantation
- Pregnant or lactating women
- Any condition potentially hampering compliance with the study protocol and follow-up schedule
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IPH2101 0.2 mg/kg
0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
|
0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
Other Names:
|
Experimental: IPH2101 2 mg/kg
2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
|
0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Patients Achieving an Objective Response
Time Frame: from start to end of study (14 months)
|
The primary end point is the rate of patients achieving an objective response (defined according to the International Myeloma Working Group uniform response criteria), including minimal response, (as derived from the European Society for Blood and Marrow Transplantation criteria), achieved at any time until end of study and confirmed on two consecutive assessments at 4 weeks interval.
|
from start to end of study (14 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Assessment
Time Frame: Adverse events collected from screening visit (date of signature of Inform Consent Form) up to the End of Study, up to 14 months
|
adverse events, physical examination and biological changes during the whole clinical trial.
|
Adverse events collected from screening visit (date of signature of Inform Consent Form) up to the End of Study, up to 14 months
|
Pharmacodynamics of IPH2101
Time Frame: from start to end of study (14 months)
|
biological activity of IPH2101 on KIR occupancy at End of Treatment
|
from start to end of study (14 months)
|
Secondary Anti-tumor Activity
Time Frame: from start to end of study (14 months)
|
Definition of active Multiple Myeloma: Evidence of progression based on the IMWG criteria for progressive disease in myeloma and any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder :
|
from start to end of study (14 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nikhil Munshi, MD, Dana-Farber Cancer Institute- Medical Oncology- Boston MA-USA
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Precancerous Conditions
- Hypergammaglobulinemia
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Smoldering Multiple Myeloma
Other Study ID Numbers
- IPH2101-203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoldering Multiple Myeloma
-
Memorial Sloan Kettering Cancer CenterHealthTree FoundationRecruitingMultiple Myeloma, SmolderingUnited States
-
Regeneron PharmaceuticalsRecruiting
-
Omar Nadeem, MDJanssen, LPRecruitingMultiple Myeloma | High-risk Smoldering Multiple MyelomaUnited States
-
Icahn School of Medicine at Mount SinaiPharmacyclics LLC.TerminatedHigh Risk Smoldering Multiple MyelomaUnited States
-
Irene Ghobrial, MDJanssen Research & Development, LLCRecruitingMultiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple MyelomaUnited States
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.Active, not recruitingMultiple Myeloma | High Risk Smoldering Multiple MyelomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingSmoldering Plasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingSmoldering Plasma Cell MyelomaUnited States
-
Janssen Research & Development, LLCCompletedHigh-risk Smoldering Multiple MyelomaUnited States, United Kingdom, Belgium, Germany, France, Spain, Korea, Republic of, Australia, Israel, Greece, Sweden
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingSmoldering Plasma Cell MyelomaUnited States
Clinical Trials on IPH2101
-
Innate PharmaCompleted
-
Innate PharmaCompleted
-
Innate PharmaCompletedPatients With Multiple Myeloma Experiencing a | First or Second RelapseUnited States